The "Sanfilippo Syndrome Type A (MPS IIIA) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Sanfilippo Syndrome Type A (MPS IIIA) market. A detailed picture of the Sanfilippo Syndrome Type A (MPS IIIA) pipeline landscape is provided, which includes the disease overview and Sanfilippo Syndrome Type A (MPS IIIA) treatment guidelines.
The assessment part of the report embraces in-depth Sanfilippo Syndrome Type A (MPS IIIA) commercial assessment and clinical assessment of the Sanfilippo Syndrome Type A (MPS IIIA) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sanfilippo Syndrome Type A (MPS IIIA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Sanfilippo Syndrome Type A (MPS IIIA) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Sanfilippo Syndrome Type A (MPS IIIA) treatment.
- Sanfilippo Syndrome Type A (MPS IIIA) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Sanfilippo Syndrome Type A (MPS IIIA) market.
Scope of the Report
- The Sanfilippo Syndrome Type A (MPS IIIA) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Sanfilippo Syndrome Type A (MPS IIIA) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Sanfilippo Syndrome Type A (MPS IIIA) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Sanfilippo Syndrome Type A (MPS IIIA) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Sanfilippo Syndrome Type A (MPS IIIA).
Key Topics Covered
1. Report Introduction
2. Sanfilippo Syndrome Type A (MPS IIIA)
2.1. Overview
2.2. History
2.3. Sanfilippo Syndrome Type A (MPS IIIA) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Sanfilippo Syndrome Type A (MPS IIIA) Diagnosis
2.6.1. Diagnostic Guidelines
3. Sanfilippo Syndrome Type A (MPS IIIA) Current Treatment Patterns
3.1. Sanfilippo Syndrome Type A (MPS IIIA) Treatment Guidelines
4. Sanfilippo Syndrome Type A (MPS IIIA) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Sanfilippo Syndrome Type A (MPS IIIA) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Sanfilippo Syndrome Type A (MPS IIIA) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Sanfilippo Syndrome Type A (MPS IIIA) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Sanfilippo Syndrome Type A (MPS IIIA) Late Stage Products (Phase-III)
7. Sanfilippo Syndrome Type A (MPS IIIA) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Sanfilippo Syndrome Type A (MPS IIIA) Discontinued Products
13. Sanfilippo Syndrome Type A (MPS IIIA) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Sanfilippo Syndrome Type A (MPS IIIA) Key Companies
15. Sanfilippo Syndrome Type A (MPS IIIA) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Sanfilippo Syndrome Type A (MPS IIIA) Unmet Needs
18. Sanfilippo Syndrome Type A (MPS IIIA) Future Perspectives
19. Sanfilippo Syndrome Type A (MPS IIIA) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Companies Mentioned
- Swedish Orphan Biovitrum
- BioMarin Pharmaceutical
- LYSOGENE
- Abeona Therapeutics, Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rqezex
View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005069/en/
Contacts:
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900